Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| CD8-positive, alpha-beta T cell | 5 studies | 25% ± 4% | |
| CD4-positive, alpha-beta T cell | 4 studies | 27% ± 7% | |
| B cell | 3 studies | 21% ± 5% | |
| plasmablast | 3 studies | 34% ± 13% | |
| neural crest cell | 3 studies | 24% ± 6% | |
| epithelial cell | 3 studies | 20% ± 1% | |
| erythroblast | 3 studies | 45% ± 15% | |
| hematopoietic precursor cell | 3 studies | 26% ± 11% | |
| natural killer cell | 3 studies | 31% ± 9% | |
| effector CD8-positive, alpha-beta T cell | 3 studies | 22% ± 5% |
Insufficient scRNA-seq data for expression of GINS2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| skin | 98% | 450.85 | 1768 / 1809 | 97% | 19.86 | 456 / 472 |
| ovary | 96% | 115.38 | 172 / 180 | 88% | 12.67 | 378 / 430 |
| uterus | 80% | 97.18 | 136 / 170 | 99% | 41.20 | 455 / 459 |
| bladder | 81% | 76.05 | 17 / 21 | 95% | 25.95 | 480 / 504 |
| thymus | 93% | 103.00 | 609 / 653 | 83% | 12.63 | 500 / 605 |
| breast | 80% | 129.51 | 366 / 459 | 96% | 24.40 | 1068 / 1118 |
| intestine | 75% | 226.12 | 729 / 966 | 94% | 29.13 | 498 / 527 |
| stomach | 74% | 111.58 | 267 / 359 | 93% | 23.64 | 267 / 286 |
| esophagus | 74% | 203.42 | 1073 / 1445 | 89% | 16.61 | 163 / 183 |
| brain | 98% | 131.29 | 2599 / 2642 | 58% | 10.27 | 407 / 705 |
| lung | 70% | 95.14 | 402 / 578 | 86% | 19.16 | 992 / 1155 |
| prostate | 98% | 172.48 | 239 / 245 | 48% | 4.63 | 243 / 502 |
| pancreas | 68% | 49.14 | 222 / 328 | 63% | 8.01 | 113 / 178 |
| liver | 70% | 101.85 | 158 / 226 | 59% | 7.30 | 240 / 406 |
| kidney | 72% | 79.55 | 64 / 89 | 51% | 4.67 | 461 / 901 |
| adrenal gland | 93% | 101.83 | 240 / 258 | 28% | 4.69 | 65 / 230 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 52.09 | 29 / 29 |
| spleen | 100% | 319.46 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 42.88 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 19.34 | 1 / 1 |
| muscle | 90% | 101.34 | 726 / 803 | 0% | 0 | 0 / 0 |
| peripheral blood | 76% | 725.97 | 704 / 929 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 55% | 4.15 | 44 / 80 |
| adipose | 55% | 43.19 | 661 / 1204 | 0% | 0 | 0 / 0 |
| heart | 35% | 23.86 | 298 / 861 | 0% | 0 | 0 / 0 |
| blood vessel | 30% | 20.10 | 400 / 1335 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0000727 | Biological process | double-strand break repair via break-induced replication |
| GO_0006268 | Biological process | DNA unwinding involved in DNA replication |
| GO_0000811 | Cellular component | GINS complex |
| GO_0071162 | Cellular component | CMG complex |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0005634 | Cellular component | nucleus |
| GO_0005515 | Molecular function | protein binding |
| Gene name | GINS2 |
| Protein name | GINS complex subunit 2 DNA replication complex GINS protein PSF2 (GINS complex subunit 2) |
| Synonyms | HSPC037 DC5 CGI-122 PSF2 |
| Description | FUNCTION: Required for correct functioning of the GINS complex, a complex that plays an essential role in the initiation of DNA replication, and progression of DNA replication forks . GINS complex is a core component of CDC45-MCM-GINS (CMG) helicase, the molecular machine that unwinds template DNA during replication, and around which the replisome is built . . |
| Accessions | Q9Y248 ENST00000253462.8 M0QXS3 M0R043 ENST00000596233.1 ENST00000595355.5 |
